感染性原生主动脉瘤腔内与开放修复结局的系统评价与荟萃分析
该系统评价与荟萃分析纳入34项研究,比较开放手术修复(OSR)与腔内动脉瘤修复(EVAR)治疗感染性原生主动脉瘤(INAA)的结局。EVAR的30天死亡率显著低于OSR(OR 0.2,95%CI 0.1-0.6),但感染相关并发症风险显著增高(OR 1.9,95%CI 1.0-3.7)。EVAR可作为低风险感染控制良好或开放手术高风险患者的替代选择。
要点
- EVAR组30天死亡率显著低于OSR组(OR 0.2,95%CI 0.1-0.6)。
- EVAR组感染相关并发症风险显著高于OSR组(OR 1.9,95%CI 1.0-3.7)。
- 两组3个月、1年全因死亡率及动脉瘤相关死亡率无显著差异。
核心结论
- EVAR较OSR提供更好的短期生存,但感染相关并发症风险更高。
- EVAR可考虑用于低风险且感染控制良好或开放手术高风险患者的替代治疗。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE、Embase和Cochrane数据库。
- 共纳入34项研究:22项仅报告OSR,6项仅报告EVAR,6项为比较研究。
- 采用纽卡斯尔-渥太华量表和Moga-Score评估方法学质量,使用随机效应模型计算合并效应量。
主要发现
- 感染相关并发症合并估计:OSR组8.2%(95%CI 4.9%-12.2%),EVAR组23.2%(95%CI 16.1%-31.0%)。
- OSR组30天、3个月、1年全因死亡率分别为11.7%(95%CI 7.7%-16.1%)、21.6%(95%CI 16.3%-27.4%)、28.3%(95%CI 20.5%-36.7%;I2=50.47%)。
- EVAR组30天、3个月、1年全因死亡率分别为4.9%(95%CI 1.1%-10.4%)、9.4%(95%CI 2.7%-18.7%)、22.2%(95%CI 12.4%-33.7%)。
- EVAR与OSR相比,3个月死亡率(OR 0.2,95%CI 0-1.1)、1年全因死亡率(OR 0.4,95%CI 0.1-1.1)及动脉瘤相关死亡率(OR 1.4,95%CI 0.5-3.9)均无显著差异。
- 再干预发生率两组无显著差异(OR 2.6,95%CI 0.9-7.7;I2=53.7%)。
临床怎么用
- 对于INAA患者,EVAR可优先考虑用于开放手术高风险者以降低围手术期死亡。
- 选择EVAR时需警惕更高的感染相关并发症风险,应确保感染充分控制并加强随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of our systematic review and meta-analysis was to demonstrate the clinical outcomes of open surgical repair (OSR) and endovascular aneurysm repair (EVAR) for infective native aortic aneurysms (INAAs). METHODS: MEDLINE, Embase, and Cochrane Databases were searched for articles reporting OSR and/or EVAR repair of INAA. The methodological quality of included studies was assessed by the Newcastle-Ottawa scale and Moga-Score. Random-effects models were used to calculate the pooled measures. RESULTS: A total of 34 studies were included, with 22 studies reporting OSR alone, 6 studies reporting EVAR alone and 6 comparative studies for INAAs. The pooled estimates of infection-related complications (IRCs) were 8.2% (95% CI 4.9%-12.2%) in OSR cohort and 23.2% (95% CI 16.1%-31.0%) in EVAR cohort. EVAR was associated with a significantly increased risk of IRCs compared with OSR during follow-up (OR 1.9, 95% CI 1.0-3.7). As for survival outcomes, the summary estimate rate of all cause 30-day, 3-month and 1-year mortality in OSR cohort were 11.7% (95% CI 7.7%-16.1%), 21.6% (95%CI 16.3%-27.4%) and 28.3% (95% CI 20.5%-36.7%; I2=50.47%), respectively. For EVAR cohort, the summary estimate rate of all cause 30-day, 3-month and 1-year mortality were 4.9% (95% CI 1.1%-10.4%), 9.4% (95% CI 2.7%-18.7%) and 22.2% (95% CI 12.4%-33.7%), respectively. EVAR was associated with a significantly decreased of 30-day mortality (OR 0.2, 95% CI 0.1-0.6). However, no difference was found between EVAR and OSR in 3-month (OR 0.2, 95% CI 0-1.1), 1-year all-cause mortality (OR 0.4, 95% CI 0.1-1.1) or aneurysm-related mortality (OR 1.4, 95% CI 0.5-3.9). Moreover, no difference of incidence of reintervention was observed (OR 2.6, 95% CI 0.9-7.7; I2=53.7%) between two groups. CONCLUSIONS: EVAR could provide better short-term survival than OSR in patients with INAAs. However, patients undergoing EVAR suffered from higher risks of IRCs. EVAR could be considered as an alternative for low-risk patients with well-controlled infections or patients considered high-risk for open reconstruction.
引用
- Han M, Wang J, Zhao J, et al. Systematic Review and Meta-Analysis of Outcomes Following Endovascular and Open Repair for Infective Native Aortic Aneurysms. Ann Vasc Surg. 2021. PMID: 34644648. doi:10.1016/j.avsg.2021.07.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。